OCLN and diabetes mellitus: The Low dose group showed a significant upregulation of ZO-1 and MUC2 expression (p < 0.001), while Claudin-1 and Occludin also displayed notable increases (p < 0.01 and p < 0.05, respectively) in comparison to the DM group.